GENE ONLINE|News &
Opinion
Blog

2025-11-26|

New Index Combining CRP, Albumin, and Lymphocyte Levels Identified for Predicting MOFS Risk in Elderly Sepsis Patients

by GOAI
Share To

A recent study has identified a new index combining C-reactive protein (CRP), albumin levels, and lymphocyte counts as a potential tool for predicting the risk of multiple organ failure syndrome (MOFS) in elderly patients with sepsis. Researchers examined the relationship between these biomarkers and the progression of sepsis, which is known to significantly compromise physiological stability and lead to life-threatening complications. The findings suggest that this combined index may offer insights into early detection and risk assessment for MOFS in critically ill patients.

The study focused on elderly individuals diagnosed with sepsis, analyzing how CRP, albumin, and lymphocyte levels interact to reflect the severity of the condition. CRP is commonly associated with inflammation, while albumin serves as an indicator of nutritional status and overall health. Lymphocytes play a key role in immune response. By integrating these three factors into a single predictive measure, researchers aimed to provide clinicians with a more comprehensive understanding of patient prognosis during sepsis treatment. Further investigation into this index could potentially refine approaches to managing critical care cases involving MOFS risks.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 27, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top